Contact Zaffer Syed
Title CEO


Summary: Each year, over 450,000 high‐risk vascular access procedures are performed in the United States. Approximately 80,000 of these patients experience a severe bleeding complication, resulting in significant additional healthcare expenditures and placing the patient at an increased risk of death. Saranas™ is a Houston-based medical device company focused on improving patient outcomes through early detection and monitoring of internal bleeding complications. The company’s patented Early Bird™ Bleed Monitoring System enables physicians to be aware of internal bleeding events early and prior to patient symptoms. Physicians may then be able to mitigate downstream consequences by addressing the complication immediately leading to significantly reduced mortality and healthcare costs.
Need: The number of vascular access procedures is rapidly increasing. As these procedures become more prevalent and complex, complication rates continue to rise.  These complications are further aggravated by the aggressive use of anticoagulants in vascular access procedures. Multiple studies have demonstrated that patients undergoing these high-risk procedures have a 7‐20% chance of experiencing a severe internal bleeding complication. These bleeding complications increase mortality (2x), the length of hospital stay (3x) and overall cost to the health care system (60%).

Value: The company’s patented Early Bird Bleed Monitoring System for vascular access procedures enables physicians to mitigate downstream consequences by addressing bleeding complications immediately, improving patient outcomes and lowering healthcare costs. These procedures are commonly performed by Interventional Cardiologists, Vascular Surgeons and Interventional Radiologists. The system has a low-risk regulatory profile, and Saranas has recently submitted for FDA clearance via the de novo pathway and no clinical trials. In addition to pursuing strategic business partnerships, Saranas is prepared to conduct a clinical pilot launch of the Early Bird Bleed Monitoring System into select hospitals throughout the US and the Texas Medical Center in 2018 in order to demonstrate clinical utility, performance and the potential for reduction in complication frequency and associated costs. The company has perfected and protected its technology, shown excellent traction, has a well developed timeline, and favorable timing to get in the marketplace with a strong multiple ROI.